comparemela.com

Latest Breaking News On - Nivolumab - Page 4 : comparemela.com

Injectable Opdivo Can Achieve the Same Goals as IV Use in RCC

Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.

Roswell parkSaby georgeDrug administrationNetwork clinical trialsUniversity of buffaloBiomedical sciencesJacobs school of medicineRoswell park comprehensive cancer centerSubcutaneous opdivoJacobs schoolSubcutaneous versus intravenousKidney cancerRenal cell carcinoma

Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Rahul banerjeeFred hutchinson cancer centerUniversity of washingtonDivision of hematologyClinical research divisionCellular therapyCellular therapy meetingsMultiple myelomaNon hodgkin lymphoma

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

Advanced renal cell carcinomaTerm follow upRenal cell carcinomaAdvanced rccCheckmate 214Metastatic clear cell rccCtla4 inhibitionMetastatic clear cell renal carcinoma

First-Line Treatments for Advanced Clear Cell RCC

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Advanced renal cell carcinomaLine treatmentsAdvanced clear cellRenal cell carcinomaAdvanced rccClear cell renal carcinomaNon clear cell renal carcinomaIo tkiRisk stratification

Dr Tripathi on the NEMIO Trial of Durvalumab Plus Chemo With/Without Tremelimumab in MIBC

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

Abhishek tripathiOnclive tvUrothelial cancerHase 3 checkmate 901 trial

vimarsana © 2020. All Rights Reserved.